Want to join the conversation?
In 1Q16, $VRTX plans to commence a clinical trial for KALYDECO (ivacaftor) in patients with CF less than two years of age to evaluate the effect of ivacaftor on markers of CF disease in young children. $VRTX has submitted a supplemental New Drug Application, sNDA, for KALYDECO and a target review date for the sNDA is set for Feb. 6, 2016.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.